Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05748132
Other study ID # sensory index in RF
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2014
Est. completion date March 30, 2021

Study information

Verified date February 2023
Source National Cancer Institute, Egypt
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Trigeminal neuralgia (TN) is defined by the International Headache Society (IHS) as "unilateral disorder characterized by brief electric shock-like pains, abrupt in onset and termination, and limited to the distribution of one or more divisions of the trigeminal nerve". It is considered the worst type of facial pain and described as intense, sharp, stabbing, and shooting like electric shock pain. It can be triggered by touch, chewing, laughing, shaving or face wash. Interventional therapies for TN are of variable efficacy and safety, and have different results for different periods of time before the recurrence of symptoms. Interventional therapy for TN is either destructive with trigeminal nerve sensory function destroyed intentionally or non-destructive with decompression of the trigeminal nerve and preservation of its regular function. The most common procedures in treating TN pain are the use of radiofrequency (RF).Combined conventional and pulsed radiofrequency (CCPRF) achieved comparable pain relief to PRF treatment alone in patients with chronic pain, the combination of PRF and CRF would increase the effect of CRF and reduce the need for long-duration CRF (LCRF) and its attendant side effects .


Description:

Trigeminal neuralgia (TN) is defined by the International Headache Society (IHS) as "unilateral disorder characterized by brief electric shock-like pains, abrupt in onset and termination, and limited to the distribution of one or more divisions of the trigeminal nerve" . It is considered the worst type of facial pain and described as intense, sharp, stabbing, and shooting like electric shock pain. It can be triggered by touch, chewing, laughing, shaving or face wash. The IHS suggests a classification of TN as either classic (essential or idiopathic) TN (CTN) or symptomatic TN (STN; pain indistinguishable from that of CTN, but caused by a demonstrable structural lesion other than vascular compression). Treatment of TN is conservative, surgical or interventional. Pharmacotherapy with carbamazepine is tried early in cases of TN but has many side effects .Other medications can be used in the treatment of TN, include oxycarbazepine, gabapentin, pregabalin, baclofen, valproate, clonazepam, phenytoin, and lamotrigime . The most clinically appropriate treatment includes surgical microvascular decompression (MVD), stereotactic radiation therapy, gamma knife (SGK), percutaneous balloon decompression, percutaneous glycerol rhizolysis, percutaneous radiofrequency (RF) of the Gasserian ganglion (GG), and GG stimulation and neuromodulation . Interventional therapies for TN are of variable efficacy and safety, and have different results for different periods of time before the recurrence of symptoms. Interventional therapy for TN is either destructive with trigeminal nerve sensory function destroyed intentionally or non-destructive with decompression of the trigeminalnerve and preservation of its regular function. The most common procedures in treating TN pain are the use of radiofrequency (RF) . Radiofrequency thermos-coagulation of the GG is thought to selectively destroy the pain fibers by thermos-coagulation at > 65°C , that helps reduce pain and prevent triggering, but can cause bothersome dysesthesia . Another method, pulsed radiofrequency (PRF) which defined as the delivery of short pulses of RF via a needle tip, thereby a short exposure at the same temperature will result in less thermal tissue destruction . Combined conventional and pulsed radiofrequency (CCPRF) achieved comparable pain relief to PRF treatment alone in patients with chronic pain, the combination of PRF and CRF would increase the effect of CRF and reduce the need for long-duration CRF (LCRF) and its attendant side effects .


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date March 30, 2021
Est. primary completion date February 28, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patients with trigeminal neuralgia, diagnosed in accordance with the International Headache Society and with a visual analogue score (VAS) for pain of at least 7 or more for a minimum of 3 months before the intervention . - Patients on a stable analgesic regimen for 2 weeks (consisting of at least two analgesics, including anticonvulsants) before the intervention . - Patients examined by use of MRI/A of the brain to exclude secondary neuralgia. Exclusion Criteria: - Patients with severe mental or psychiatric disorders - Patients with history of drug abuse, high intracranial tension and history of MVD, SGK, balloon compression, RF treatment, or glycerol injection - The possibility of vascular loop compression and other causes of TN

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
combined conventional and pulsed RF
the classic Hartle technique is used to reach the Gasserian ganglion Sensory stimulation with the RF equipment is conducted and parathesia of the affected branch is achieved at 0.1-0.2 V (50 Hz), keeping in mind that the mandibular part of the Gasserian ganglion is ventrolateral and the ophthalmic rootlets are postrolateral. Motor pre-stimulation (2 Hz) is achieved with masseter contraction at 0.1-0.3 V . After sensory and motor stimulation, RF therapy is conducted by use of the RF generator , in the sequence: Conventional RF 1st lesion at 60 °C for 60 s then 2nd lesion at 65°C for 60 seconds then 3rd lesion at 70°C for 60 seconds Finally, PRF is applied for 360 second repeated at 45 V, with a pulse width of 10 ms and a pulse frequency of 4 Hz. The cut-off needle tip temperature is set at 42 °C. Before withdrawal of needle 1 cc xylocaine 1% + 0.5 cc dexamethasone 4mg to be given

Locations

Country Name City State
Egypt Ehab Hanafy Shaker Cairo

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute, Egypt

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Ding Y, Li H, Hong T, Zhu Y, Yao P, Zhou G. Combination of Pulsed Radiofrequency with Continuous Radiofrequency Thermocoagulation at Low Temperature Improves Efficacy and Safety in V2/V3 Primary Trigeminal Neuralgia. Pain Physician. 2018 Sep;21(5):E545-E5 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Sensory index effectiveness The relation between the sensory index and the success of the procedure defined as reduction of the Visual analogue score by 50% or more. 3 years
Secondary Number of recurrence Evaluating the recurrence rate. Recurrence of pain more than 50 % of the initial measured pain 3 years
Secondary Assessment of quality of life Quality of life score 3 Years
See also
  Status Clinical Trial Phase
Recruiting NCT05059379 - Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer Phase 3
Recruiting NCT06197581 - Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer N/A
Recruiting NCT06042946 - Microsurgical Resection of Intramedullary Spinal Cord Metastases
Completed NCT04321187 - Influence of Prostate Cancer Radiation on Aging
Terminated NCT03553212 - Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy N/A
Completed NCT02979691 - Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01 Phase 2/Phase 3
Terminated NCT03720158 - Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of Head and Neck Cancer Patients N/A
Not yet recruiting NCT05339581 - IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation N/A
Recruiting NCT05308732 - Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy Phase 1
Recruiting NCT06313450 - De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma N/A
Active, not recruiting NCT03893461 - Coagulation System In STereotactic Radiotherapy Of NSCLC
Active, not recruiting NCT03475186 - Testing Ramipril to Prevent Memory Loss in People With Glioblastoma Phase 2
Recruiting NCT06418113 - Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma Phase 1
Recruiting NCT04819685 - Application of KANG FU PEN in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury Phase 4
Completed NCT04854525 - Breast Reconstruction in Previously Irradiated Breast
Completed NCT04783818 - Adjuvant Radiotherapy's Effect on One and Two Stages Prosthetic Breast Reconstruction and on Autologous Reconstruction
Completed NCT03226925 - Mechanically-assisted Ventilation in the Treatment of Moving Tumours With Photon and Proton Therapies N/A
Recruiting NCT04901234 - Adaptive RadioTherapy for OroPharynx Cancer Phase 2
Recruiting NCT06272617 - Acupuncture for Prevention and Treatment of Oral-related Complications Caused by Radiotherapy for Head and Neck Cancer N/A
Not yet recruiting NCT05561634 - Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma Phase 2